From ClinicalTrials.gov
GLP-1 clinical trial results
290 Phase 3 trials with posted results, 146 of them named. Each page shows the results and side effects arm by arm, as the registry posts them. The newest update at source is Nov 4, 2026.
Largest first
Semaglutide trials with results
74 trials, 815,735 participants.
| Trial | Medication | People | Primary result |
|---|---|---|---|
| NCT05768945Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors | Semaglutide | 742,670 | See the trial's page: several measures or groups. |
| SELECTSemaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Semaglutide | 17,604 | Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (Participants), From randomisation (week 0) up to 240 weeks. Semaglutide: 569; Placebo: 701. |
| SOULA Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Semaglutide | 9,651 | Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke (Participants), From randomisation (week 0) up to week 265. Oral Semaglutide: 579; Placebo: 668. |
| FLOWA Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Semaglutide | 3,533 | Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (Participants), From Week 0 up to Week 234. Semaglutide: 331; Placebo: 410. |
| SUSTAIN 6Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Semaglutide | 3,297 | Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (percentage of subjects), Time from randomisation up to end of follow-up (scheduled at week 109). Semaglutide: 6.6; Placebo: 8.9. |
| SUSTAIN 11A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes | Semaglutide | 2,274 | Change From Baseline in Glycated Haemoglobin (HbA1c) (Percentage of HbA1c), Baseline (week 0), week 52. Semaglutide: -1.5; Insulin Aspart: -1.2. |
| STEP 1STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide | 1,961 | See the trial's page: several measures or groups. |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | Semaglutide | 1,879 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 40. 10 mg Tirzepatide: -2.37; 15 mg Tirzepatide: -2.46; 1 mg Semaglutide: -1.86. |
| PIONEER 3Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Semaglutide | 1,864 | See the trial's page: several measures or groups. |
| PIONEER PLUSResearch Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | Semaglutide | 1,606 | Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) (Percentage point of HbA1c), Baseline (week 0), week 52. Oral Semaglutide 14 mg: -1.5; Oral Semaglutide 25 mg: -1.9; Oral Semaglutide 50 mg: -2.1. |
| PIONEER 12A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | Semaglutide | 1,441 | See the trial's page: several measures or groups. |
| STEP UPA Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Semaglutide | 1,407 | Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight (Percentage (%) change in body weight), Baseline (week 0), End of treatment (week 72). Semaglutide 7.2 mg: -19.5; Placebo: -3.8. |
| COMBINE 1A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec | Semaglutide | 1,291 | Change in Glycated Haemoglobin (HbA1c) (Percentage point of HbA1c), Baseline (Week 0), Week 52. IcoSema: -1.60; Insulin Icodec: -0.90. |
| SUSTAIN 2Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Semaglutide | 1,231 | Change in HbA1c (Glycosylated Haemoglobin) From Baseline (percentage of glycosylated haemoglobin), Week 0, week 56. Semaglutide 0.5 mg + Sitagliptin Placebo: -1.32; Semaglutide 1.0 mg + Sitagliptin Placebo: -1.61; Sitagliptin + Semaglutide Placebo: -0.55. |
| STEP 2Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity | Semaglutide | 1,210 | See the trial's page: several measures or groups. |
| SUSTAIN 4Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes | Semaglutide | 1,089 | Change in HbA1c From Baseline (percentage), Week 0, week 30. Semaglutide 0.5mg/Week: -1.21; Semaglutide 1.0 mg/Week: -1.64; Insulin Glargine: -0.83. |
| SUSTAIN FORTEA Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Semaglutide | 961 | See the trial's page: several measures or groups. |
| STEP 4Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide | 902 | See the trial's page: several measures or groups. |
| SUSTAINEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Semaglutide | 868 | See the trial's page: several measures or groups. |
| PIONEER 2Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus | Semaglutide | 822 | See the trial's page: several measures or groups. |
| SUSTAIN 3Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Semaglutide | 813 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), Week 0, week 56. Semaglutide 1.0 mg: -1.54; Exenatide ER 2.0 mg: -0.92. |
| STRIDEA Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Semaglutide | 792 | Change in Maximum Walking Distance on a Constant Load Treadmill Test (Ratio of maximum walking distance), Baseline (week 0), end of treatment (week 52). Semaglutide: 1.21; Placebo: 1.08. |
| SUSTAIN 8Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes | Semaglutide | 788 | See the trial's page: several measures or groups. |
| SURMOUNT-5A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Semaglutide | 751 | Percent Change From Baseline in Body Weight (Percent change), Baseline, Week 72. 15 mg or MTD - Tirzepatide: -20.2; 2.4 mg or MTD - Semaglutide: -13.7. |
| PIONEER 8Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | Semaglutide | 731 | See the trial's page: several measures or groups. |
| PIONEER 1Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only | Semaglutide | 703 | See the trial's page: several measures or groups. |
| COMBINE 2A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | Semaglutide | 683 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage point of HbA1c), Baseline (week 0), (week 52). IcoSema: -1.40; Semaglutide: -0.86. |
| OASIS 1Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Semaglutide | 667 | Percentage Change in Body Weight (Percentage (%) change in body weight), Baseline (week 0), end-of-treatment (week 68). Oral Semaglutide 50 mg: -15.8; Placebo: -2.2. |
| STEP HFpEF DMResearch Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes | Semaglutide | 617 | Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score (Score on a scale), Baseline (week 0), end of treatment (week 52). Semaglutide 2.4 mg: 14.4; Placebo: 7.6. |
| STEP 3Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program | Semaglutide | 611 | See the trial's page: several measures or groups. |
| SUSTAINA Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes | Semaglutide | 601 | Number of Treatment Emergent Adverse Events (TEAEs) (Number of events), Weeks 0-56. Semaglutide 0.5 mg: 909; Semaglutide 1.0 mg: 954; Additional OAD: 269. |
| SUSTAIN 10Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Semaglutide | 577 | Change in HbA1c (Percentage of glycosylated haemoglobin), Week 0, week 30. Semaglutide 1.0 mg: -1.7; Liraglutide 1.2 mg: -1.1. |
| NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Semaglutide | 573 | Change in Glycated Haemoglobin (HbA1c) [Noninferiority] (Percentage point of HbA1c), From baseline (week 0) to end of treatment (week 40). Insuline Glargine U100 (Reduced) + Semaglutide: -1.37; Insuline Glargine U100 (Titrated): -0.65. |
| STEP-HFpEFResearch Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | Semaglutide | 529 | Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (Score on a scale), From baseline (week 0) to end of treatment (week 52). Semaglutide 2.4 mg: 16.8; Placebo: 10.3. |
| PIONEER 11A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes | Semaglutide | 521 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage of HbA1c), Baseline (Week 0), Week 26. Oral Semaglutide 3 mg: -1.1; Oral Semaglutide 7 mg: -1.5; Oral Semaglutide 14 mg: -1.6; Placebo: -0.2. |
| NCT05649137A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Semaglutide | 512 | Relative Change in Body Weight (Percentage (%) change in body weight), Baseline (week 0), End of treatment (week 72). Semaglutide 7.2 mg: -13.5; Semaglutide 2.4 mg: -10.7; Placebo: -4.0. |
| PIONEER 7Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | Semaglutide | 504 | See the trial's page: several measures or groups. |
| WAYFINDStudy of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Semaglutide | 457 | Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups (percentage of participants), Week 72. SEMA + CILO/FIR FDC: 13.7; PTM SEMA + PTM CILO/FIR: 8.3. |
| NCT05064735Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Semaglutide | 407 | Percentage Change in Body Weight (Percentage change in body weight), Baseline (week 0), end of treatment (week 68). Semaglutide 2.4 mg: -14.2; Placebo: -2.5. |
| STEP 6STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity | Semaglutide | 401 | Change in Body Weight (%) (Percentage change), Baseline (week 0), week 68. Semaglutide 1.7 mg: -9.9; Semaglutide 2.4 mg: -13.4; Placebo: -1.9. |
| SUSTAIN 5Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes | Semaglutide | 397 | Change in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated hemoglobin), Week 0, week 30. Semaglutide 0.5 mg: -1.45; Semaglutide 1.0 mg: -1.85; Placebo: -0.09. |
| NCT05478252A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes | Semaglutide | 388 | Change in Glycosylated Haemoglobin (HbA1c) (Percentage of glycosylated haemoglobin), From baseline (week 0) to end of treatment (week 28). Semaglutide J: -1.7; Semaglutide B: -1.6. |
| SUSTAIN1Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes | Semaglutide | 388 | Change in HbA1c (Glycosylated Haemoglobin) (Percentage of HbA1c), Week 0, week 30. Semaglutide 0.5 mg: -1.47; Semaglutide 1.0 mg: -1.56; Placebo: -0.00. |
| STEP7Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. | Semaglutide | 375 | Change From Baseline in Body Weight (Percentage [%]) (Percentage change), Baseline (week 0), week 44. Semaglutide 2.4 mg: -12.5; Placebo: -3.6. |
| STEP 8Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Semaglutide | 338 | Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) (Percentage of body weight), Baseline (week 0), week 68. Semaglutide 2.4 mg: -16.4; Liraglutide 3.0 mg: -6.4. |
| PIONEER 5Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Semaglutide | 324 | See the trial's page: several measures or groups. |
| SUSTAINA Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes | Semaglutide | 308 | Number of Treatment Emergent Adverse Events (TEAEs) (Number of events), Weeks 0-30. Semaglutide 0.5 mg: 228; Semaglutide 1.0 mg: 197; Sitagliptin: 186. |
| OASIS 4Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range | Semaglutide | 307 | Percentage Change in Body Weight (Percentage change in body weight), Baseline (week 0), end of treatment (week 64). Oral Semaglutide 25 mg: -14.4; Placebo: -2.5. |
| STEP 5Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide | 304 | See the trial's page: several measures or groups. |
| SUSTAIN 9Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus | Semaglutide | 302 | Change in HbA1c (Percentage of HbA1c), Week 0, week 30. Semaglutide 1.0 mg: -1.6; Placebo: -0.2. |
| NCT04515849A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus | Semaglutide | 248 | The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks (Percentage change), Baseline to the end of 14 weeks of dosing. Cotadutide 100 ug: -10.96; Cotadutide 300 µg: -40.47; Cotadutide 600 µg: -44.60; Placebo ug: 4.60. |
| STEP12A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range | Semaglutide | 242 | Change in Body Weight (%) (Percentage change in body weight), Baseline (week 0), end of treatment (week 44). Semaglutide 2.4 mg: -12.2; Placebo: -2.2. |
| STEP 10Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Semaglutide | 207 | Change in Body Weight (Percentage [%]) (Percentage (%) of body weight), From randomisation (week 0) to end of treatment (week 52). Semaglutide 2.4 mg: -14.4; Placebo: -2.7. |
| OASIS 2Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Semaglutide | 201 | Percent Change From Baseline in Body Weight (Percent change of body weight), Baseline (week 0), week 68. Oral Semaglutide 50 mg: -14.9; Oral Semaglutide Placebo: -1.5. |
| NCT04102189A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Semaglutide | 201 | Change in Body Mass Index (BMI) (Percentage [%]) (Percentage change of BMI), Baseline (week 0), week 68. Semaglutide 2.4 mg: -16.2; Placebo: -0.1. |
| NCT04998136Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Semaglutide | 150 | Change in Body Weight (%) : In-trial Observation Period (Percentage of body weight), Baseline (week 0), end of treatment (week 44). Semaglutide: -16.4; Placebo: -2.6. |
| NCT05813912A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | Semaglutide | 148 | See the trial's page: several measures or groups. |
| NCT04944992A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Semaglutide | 145 | Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks (Percent Reduction), Baseline and up to ~24 Weeks. Efinopegdutide: 72.7; Semaglutide: 42.3. |
| PIONEER TEENSA Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Semaglutide | 132 | Change From Baseline (Week 0) to Week 26 in Glycosylated Haemoglobin (HbA1c)- Percentage Point (Percentage point), Baseline (Week 0), Week 26. Oral Semaglutide: -1.0; Placebo: -0.3. |
| ADJUST-T1DADJUnct Semaglutide Treatment in Type 1 Diabetes | Semaglutide | 115 | Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group (Participants), 26 weeks. Semaglutide: 13; Control: 0. |
| NCT03987074Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | Semaglutide | 109 | Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) (percentage of participants), First dose date up to Week 24 plus 30 days. Semaglutide: 81.0; Semaglutide + Firsocostat 20 mg: 86.4; Semaglutide + Cilofexor 30 mg: 81.8; Semaglutide + Cilofexor 100 mg: 72.7; Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg: 90.5. |
| NCT04019197Effects of Semaglutide in HIV-Associated Lipohypertrophy | Semaglutide | 108 | Effects of Semaglutide on Quantity of Ectopic Fat (Total Pericardial Fat) at Week 32 Compared to Baseline (mL), 32 weeks. Semaglutide: -1.85; Placebo: 0.00. |
| REMODELA Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) | Semaglutide | 106 | See the trial's page: several measures or groups. |
| NCT03987451A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage | Semaglutide | 71 | Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement With No Worsening of Non-Alcoholic Steatohepatitis (NASH) After 48 Weeks (Percentage of participants), Week 48. Semaglutide 2.4 mg: 10.6; Placebo: 29.2. |
| BARI-STEPSemaglutide 2.4 mg in Patients With Poor Weight-loss | Semaglutide | 70 | Percentage Weight Change (percentage change), Baseline and week 68. Placebo: 0.4; Semaglutide 2.4mg: -18.0. |
| TEALTreating PCOS With Semaglutide vs Active Lifestyle Intervention | Semaglutide | 60 | Change in Hepatic Fat Fraction (Change in percentage of liver fat), Baseline and 12 weeks. Diet Intervention: -1.41; GLP-1 Intervention: -1.84. |
| NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | Semaglutide | 51 | See the trial's page: several measures or groups. |
| NCT05520775Semaglutide for Alcohol Use Disorder | Semaglutide | 48 | Change in Alcohol Consumed (grams), Baseline (Week 0) to post-medication (Week 8). Semaglutide: -32.72; Sham/Placebo: -6.95. |
| NCT05530577Effects of Semaglutide on Nicotine Intake | Semaglutide | 24 | Change in Nicotine Self-Administration (Number of cigarettes), Baseline (Week 0) to post-medication (Week 8). Semaglutide: -0.8; Sham/Placebo: -0.5. |
| NCT05891496A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Semaglutide | 23 | Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) (Differentially expressed genes), Baseline (week 0), week 12. Semaglutide: 41.25; Placebo: 21.00. |
| NCT05786521Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults | Semaglutide | 20 | Lean Body Mass Change (g), Baseline to 20 weeks. Semaglutide and Lifestyle Intervention: -1730.6; Lifestyle Intervention: -421. |
| RAISE-KTEffect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | Semaglutide | 15 | Kidney Transplant Eligibility (Participants), Ascertained at the end of 9 months. Semaglutide: 3; Placebo: 2. |
| NCT05788965Semaglutide in CFRD | Semaglutide | 8 | See the trial's page: several measures or groups. |
| NOVO-GLP1Treatment of GLP-1 for Diabetic Bariatric Patients | Semaglutide | 3 | See the trial's page: several measures or groups. |
Updated automatically
What just changed in the registry
- TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- TrialSemaglutide study now completed (was unknown): The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- TrialTirzepatide study now recruiting (was not yet recruiting): AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- TrialTirzepatide study now recruiting (was not yet recruiting): A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- TrialNew Liraglutide study registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Written from each source's own record as it changes. Every change on GLPcompare
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.